Live Breaking News & Updates on Conventional Therapy

Stay updated with breaking news from Conventional therapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Ascendis Presents TransCon™ PTH Data at the American Thyroid Association Annual Meeting

– At Week 26, 81% of patients in Phase 3 PaTHway Trial with chronic post-surgical hypoparathyroidism, the most common cause of this disease, achieved independence from conventional therapy while maintaining normocalcemia following treatment with TransCon PTH – Post-surgical patients treated with TransCon PTH self-reported significant improvements in disease-related symptoms, physical functioning, and daily life compared to those on placebo – Results for post-surgical patients (n=70) comparable t ....

New Jersey , United States , Baden Wüberg , Redwood City , Ascendis Pharma , Aimee Shu , Endocrinology Medical Sciences At Ascendis Pharma , Clinical Development , European Union , American Thyroid Association , Item Short Form Survey , Vice President , Endocrinology Medical Sciences , Hypoparathyroidism Patient Experience Scale , Trial Sub Analysis , About Ascendis Pharma , Palo Alto , Conventional Therapy , American Thyroid Association , Clinical Trial Data , Treatment Option , Ormal Serum Calcium Levels , Patients With Chronic ,

Why we should set healthy boundaries in friendships

If a friend continues to overstep our boundaries after we’ve spelt it out to them countless times, it may be time to acknowledge that the friendship might not be worth another shot. ....

Nhealthy Boundaries , Platonic Relationships , Overstepping Boundaries , Conventional Therapy , Navigating Friendships ,

Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint: Swedish Orphan Biovitrum AB (2)

75% of subjects in the DISSOLVE I extension phase on active treatment were responders through 12 months of. ....

United States , Carsten Brunn , Anders Ullman , Thomas Kudsk Larsenhead , Selecta Biosciences , Guido Oelkers , Peter Traber , Prnewswire Selecta Biosciences Inc , Sobi Investor Relations Team , Exchange Commission , Company Imm , Selecta Biosciences Inc , Head Of Research Development , Chief Medical Officer , Chief Executive Officer , Medical Affairs , Randomized Double Blind , Placebo Controlled Study , Gout Refractory , Conventional Therapy , Inc Selecta Biosciences , Greater Boston , North America , Middle East , Forward Looking Statementsany , Private Securities Litigation Reform Act ,

Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint: Swedish Orphan Biovitrum AB (3)

75% of subjects in the DISSOLVE I extension phase on active treatment were responders through 12 months of. ....

United States , Carsten Brunn , Anders Ullman , Thomas Kudsk Larsenhead , Selecta Biosciences , Guido Oelkers , Peter Traber , Prnewswire Selecta Biosciences Inc , Sobi Investor Relations Team , Exchange Commission , Company Imm , Selecta Biosciences Inc , Head Of Research Development , Chief Medical Officer , Chief Executive Officer , Medical Affairs , Randomized Double Blind , Placebo Controlled Study , Gout Refractory , Conventional Therapy , Inc Selecta Biosciences , Greater Boston , North America , Middle East , Forward Looking Statementsany , Private Securities Litigation Reform Act ,

Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint: Swedish Orphan Biovitrum AB

/PRNewswire/ Selecta Biosciences, Inc. (NASDAQ: SELB) and Sobi®, today announced positive topline results from the Phase 3 DISSOLVE I & II placebo. ....

United States , Carsten Brunn , Anders Ullman , Blaine Davis , Selecta Biosciences , Thomas Kudsk Larsen , Guido Oelkers , Peter Traber , Sobi Investor Relations Team , Exchange Commission , Company Imm , Selecta Biosciences Inc , Head Of Research Development , Chief Medical Officer , Chief Executive Officer , Medical Affairs , Randomized Double Blind , Placebo Controlled Study , Gout Refractory , Conventional Therapy , Greater Boston , North America , Middle East , Private Securities Litigation Reform Act , Annual Report , Sobi Media ,